Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens

The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis

GlobeNewsWire • Jun 8, 2026

Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • May 13, 2026

Enovis Q1 Earnings Call Highlights

Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.

MarketBeat • May 10, 2026

Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript

Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Enovis Announces First Quarter 2026 Results

Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

GlobeNewsWire • May 7, 2026

Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates

Enovis (ENOV) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.81 per share a year ago.

Zacks Investment Research • May 7, 2026

Enovis (ENOV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 30, 2026

Omnicell (OMCL) Q1 Earnings and Revenues Surpass Estimates

Omnicell (OMCL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.26 per share a year ago.

Zacks Investment Research • Apr 28, 2026

Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock

Enovis (ENOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research • Apr 22, 2026

Analyst Backs Enovis On Cash Flow Turnaround

The firm argued that while the stock has lagged over the past two years, execution on cash flow could unlock multiple expansion opportunities.

Benzinga • Apr 17, 2026